US5939391A
(en)
*
|
1993-03-31 |
1999-08-17 |
Pro-Neuron, Inc. |
Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
|
US6610654B2
(en)
|
1993-03-31 |
2003-08-26 |
Wellstat Therapeutics Corporation |
Inhibitor of stem cell proliferation and uses thereof
|
AT403167B
(de)
*
|
1994-11-14 |
1997-11-25 |
Immuno Ag |
Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
|
DE19514310A1
(de)
*
|
1995-04-18 |
1996-10-24 |
Univ Ludwigs Albert |
Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
|
DE19542051C2
(de)
|
1995-11-10 |
2000-03-23 |
Asta Medica Ag |
Gentechnisch veränderte tumorigene Zellinien und Verwendung derselben für die Testung von Antitumor-Wirkstoffen
|
DE69626960T2
(de)
|
1995-11-16 |
2003-11-06 |
Matsushita Electric Ind Co Ltd |
Verfahren und vorrichtung zur urinanalyse, verfahren zur messung optischer rotation und polarimeter
|
US5861483A
(en)
|
1996-04-03 |
1999-01-19 |
Pro-Neuron, Inc. |
Inhibitor of stem cell proliferation and uses thereof
|
FR2749857B1
(fr)
*
|
1996-06-12 |
1998-08-14 |
Centre Nat Rech Scient |
Generation de molecules replicatives in vivo
|
JP2001503257A
(ja)
*
|
1996-10-18 |
2001-03-13 |
バレンティス・インコーポレーテッド |
Il―12遺伝子発現および送達系および使用
|
FR2762615B1
(fr)
*
|
1997-04-28 |
1999-07-16 |
Inst Nat Sante Rech Med |
Nouveau site interne d'entree des ribosomes et vecteur le contenant
|
US20030138808A1
(en)
*
|
1998-02-19 |
2003-07-24 |
Simard John J.L. |
Expression vectors encoding epitopes of target-associated antigens
|
CA2358385C
(en)
|
1998-12-31 |
2013-08-06 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
WO2000039302A2
(en)
*
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
CA2358915C
(en)
|
1998-12-31 |
2010-06-01 |
Chiron Corporation |
Modified hiv env polypeptides
|
US6610508B1
(en)
*
|
1999-03-08 |
2003-08-26 |
Anadys Pharmaceuticals, Inc. |
Translation driver system and methods for use thereof
|
AU2001231171B2
(en)
*
|
2000-01-28 |
2007-01-04 |
The Scripps Research Institute |
Synthetic internal ribosome entry sites and methods of identifying same
|
US20030215425A1
(en)
*
|
2001-12-07 |
2003-11-20 |
Simard John J. L. |
Epitope synchronization in antigen presenting cells
|
US6861234B1
(en)
|
2000-04-28 |
2005-03-01 |
Mannkind Corporation |
Method of epitope discovery
|
JP2001299361A
(ja)
*
|
2000-04-28 |
2001-10-30 |
Oriental Yeast Co Ltd |
溶液安定性の組換えヒトクレアチンキナーゼヘテロダイマー
|
DE60142615D1
(de)
*
|
2000-04-28 |
2010-09-02 |
Mannkind Corp |
Epitop-synchronisierung in antigen präsentierenden zellen
|
NZ523220A
(en)
*
|
2000-06-19 |
2005-03-24 |
Gtc Biotherapeutics Inc |
Transgenically produced platelet derived growth factor
|
JP4510242B2
(ja)
*
|
2000-07-11 |
2010-07-21 |
キヤノン株式会社 |
薄膜形成方法
|
WO2002096948A2
(en)
*
|
2001-01-29 |
2002-12-05 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
CA2436092A1
(en)
*
|
2001-01-29 |
2002-08-08 |
Idec Pharmaceutical Corporation |
Modified antibodies and methods of use
|
WO2003004657A1
(en)
*
|
2001-07-05 |
2003-01-16 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
|
EP2412242A3
(en)
|
2001-07-05 |
2012-06-13 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
CA2458995C
(en)
*
|
2001-08-31 |
2013-04-30 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
US20030170614A1
(en)
*
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
ITMI20012110A1
(it)
*
|
2001-10-12 |
2003-04-12 |
Keryos Spa |
Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
|
US20030108524A1
(en)
*
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
CN1313617C
(zh)
*
|
2001-11-07 |
2007-05-02 |
曼康公司 |
编码靶相关抗原表位的表达载体及其设计方法
|
EP2022799A2
(en)
*
|
2001-11-16 |
2009-02-11 |
Biogen Idec Inc. |
Polycistronic expression of antibodies
|
US20030157641A1
(en)
*
|
2001-11-16 |
2003-08-21 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
WO2003059932A2
(en)
*
|
2001-12-27 |
2003-07-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods of inducing or enhancing connective tissue repair
|
US9738907B2
(en)
|
2002-02-01 |
2017-08-22 |
Oxford Biomedica (Uk) Limited |
Viral vector
|
EP1504108B1
(en)
*
|
2002-02-01 |
2013-04-17 |
Oxford Biomedica (UK) Limited |
Lentiviral vector
|
ES2362273T3
(es)
*
|
2002-06-14 |
2011-06-30 |
Chromagenics B.V. |
Método para la producción simultánea de múltiples proteínas; vectores y células para su uso en el mismo.
|
US7344886B2
(en)
|
2002-11-29 |
2008-03-18 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
US20050032728A1
(en)
*
|
2002-12-17 |
2005-02-10 |
Sidney Kimmel Cancer Center |
Tumor suppression through bicistronic co-expression of p53 and p14ARF
|
DE60312039T2
(de)
*
|
2002-12-20 |
2007-11-08 |
Chromagenics B.V. |
Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
|
GB0326798D0
(en)
*
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
US20080077999A1
(en)
*
|
2004-03-23 |
2008-03-27 |
Eisai R&D Management Co., Ltd. |
Using Nonhuman Animal Model, Method of Measuring Transcription Activity Method of Measuring Cell Quantity and Method of Measuring Tumor Volume
|
TW200613554A
(en)
*
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
ES2384391T3
(es)
*
|
2004-11-08 |
2012-07-04 |
Chromagenics B.V. |
Selección de células hospedantes que expresan proteína a altos niveles
|
US20060195935A1
(en)
|
2004-11-08 |
2006-08-31 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US20100136616A1
(en)
*
|
2004-11-08 |
2010-06-03 |
Chromagenics B.V. |
Selection of Host Cells Expressing Protein at High Levels
|
CA2610619A1
(en)
*
|
2005-05-31 |
2006-12-07 |
University Of Rochester |
Method of determining immune enhancement of virus infectivity using fc receptor-transfected cell lines
|
EP1910550A4
(en)
|
2005-07-21 |
2009-11-04 |
Abbott Lab |
MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS
|
US20080124760A1
(en)
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
CN101743306A
(zh)
|
2007-03-23 |
2010-06-16 |
威斯康星校友研究基金会 |
体细胞重编程
|
EP2205249B1
(en)
|
2007-09-28 |
2018-11-07 |
Intrexon Corporation |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
ES2587395T3
(es)
|
2008-06-04 |
2016-10-24 |
Cellular Dynamics International, Inc. |
Procedimientos para la producción de células IPS usando un enfoque no vírico
|
WO2010019569A1
(en)
|
2008-08-12 |
2010-02-18 |
Cellular Dynamics International. Inc. |
Methods for the production of ips cells
|
KR101361416B1
(ko)
|
2008-10-08 |
2014-02-21 |
인트렉손 코포레이션 |
다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
|
CN102812040A
(zh)
*
|
2009-10-30 |
2012-12-05 |
雅培制药有限公司 |
Sorf构建体和多基因表达
|
EP2640743B1
(en)
|
2010-11-16 |
2016-10-05 |
Excelimmune, Inc. |
Methods for producing recombinant proteins
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
WO2013161958A1
(ja)
|
2012-04-27 |
2013-10-31 |
日本ケミカルリサーチ株式会社 |
新規な発現ベクター
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
CA3031955A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
MX2019003768A
(es)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Moleculas de enlace especificas de hpv.
|
CA3045323A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
BR112019011207A2
(pt)
|
2016-12-05 |
2019-10-08 |
Juno Therapeutics Inc |
produção de células modificadas para terapia celular adotiva
|
JP2020505034A
(ja)
|
2017-01-20 |
2020-02-20 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞表面コンジュゲートならびに関連する細胞組成物および方法
|
DE102017103383A1
(de)
|
2017-02-20 |
2018-08-23 |
aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) |
System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
|
AU2018250336A1
(en)
|
2017-04-07 |
2019-09-26 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
CN111201438A
(zh)
|
2017-06-02 |
2020-05-26 |
朱诺治疗学股份有限公司 |
与和细胞疗法相关的毒性有关的制品和方法
|
WO2019027850A1
(en)
|
2017-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS
|
JP2020530997A
(ja)
*
|
2017-08-08 |
2020-11-05 |
サンガモ セラピューティクス, インコーポレイテッド |
キメラ抗原受容体媒介性細胞標的化
|
BR112020001601A2
(pt)
|
2017-08-09 |
2020-08-11 |
Juno Therapeutics Inc |
métodos e composições para preparar células geneticamente manipuladas
|
WO2019051335A1
(en)
|
2017-09-07 |
2019-03-14 |
Juno Therapeutics, Inc. |
METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
|
EP4215543A3
(en)
|
2017-10-03 |
2023-10-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
US11623961B2
(en)
|
2017-11-01 |
2023-04-11 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
CN111902159A
(zh)
|
2017-11-01 |
2020-11-06 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体
|
CN109837293A
(zh)
*
|
2017-11-24 |
2019-06-04 |
康码(上海)生物科技有限公司 |
一种能够增强蛋白质合成效率的串联dna元件
|
US20210128616A1
(en)
|
2017-12-08 |
2021-05-06 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
SG11202005272SA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Process for producing a composition of engineered t cells
|
WO2019113556A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
BR112020020245A2
(pt)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
Métodos de produzir células expressando um receptor recombinante e composições relacionadas
|
RU2020136054A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
Т-клетки, экспрессирующие рекомбинантный рецептор, соответствующие полинуклеотиды и способы
|
EP3787751A1
(en)
|
2018-05-03 |
2021-03-10 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
AU2019316647A1
(en)
|
2018-08-09 |
2021-02-25 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
JP2021533746A
(ja)
|
2018-08-09 |
2021-12-09 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞およびその組成物を生成するための方法
|
CA3111789A1
(en)
|
2018-09-11 |
2020-03-19 |
Juno Therapeutics, Inc. |
Methods for mass spectrometry analysis of engineered cell compositions
|
JP2022512872A
(ja)
|
2018-10-31 |
2022-02-07 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞の選択および刺激のための方法ならびにそのための装置
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
CA3117720A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
KR20220016474A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 cd247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
|
CN112439056B
(zh)
*
|
2019-08-28 |
2022-05-31 |
中国农业科学院生物技术研究所 |
基于自组装铁蛋白纳米抗原颗粒及由其制备的o型口蹄疫疫苗和应用
|
US20220333132A1
(en)
|
2019-09-03 |
2022-10-20 |
Sana Blotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
AU2020377043A1
(en)
|
2019-10-30 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
JP2022554353A
(ja)
|
2019-11-07 |
2022-12-28 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法と(s)-3-[4-(4-モルホリン-4-イルメチル-ベンジルオキシ)-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル]-ピペリジン-2,6-ジオンとの併用
|
WO2021151008A1
(en)
|
2020-01-24 |
2021-07-29 |
Juno Therapuetics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞形質導入のための方法
|
KR20220152220A
(ko)
|
2020-02-12 |
2022-11-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cd19-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
WO2021249116A1
(en)
|
2020-06-10 |
2021-12-16 |
Sichuan Clover Biopharmaceuticals, Inc. |
Coronavirus vaccine compositions, methods, and uses thereof
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
CN116802203A
(zh)
|
2020-11-04 |
2023-09-22 |
朱诺治疗学股份有限公司 |
从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法
|
CA3210581A1
(en)
|
2021-03-22 |
2022-09-29 |
Neil HAIG |
Methods of determining potency of a therapeutic cell composition
|
EP4313126A1
(en)
|
2021-03-29 |
2024-02-07 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023017115A1
(en)
|
2021-08-11 |
2023-02-16 |
Iba Lifesciences Gmbh |
Fractionation of cells based on a marker protein
|
WO2023019229A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
WO2023017494A1
(en)
|
2021-08-13 |
2023-02-16 |
Triovance Holding Llc |
A skin substitute composition and methods of producing and using the same
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023115049A1
(en)
|
2021-12-17 |
2023-06-22 |
Umoja Biopharma, Inc. |
Cytotoxic innate lymphoid cell and uses thereof
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023205705A2
(en)
|
2022-04-20 |
2023-10-26 |
Bluesphere Bio, Inc. |
Allogeneic t cells for treatment of hematological malignancies
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023240282A1
(en)
|
2022-06-10 |
2023-12-14 |
Umoja Biopharma, Inc. |
Engineered stem cells and uses thereof
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|